The collaboration with Invenra is likely to be viewed positively by investors as it represents an expansion of Catalent's capabilities and product pipeline in the rapidly growing biotech sector, specifically in the area of ADCs. This could lead to increased investor confidence and potentially a positive impact on Catalent's stock price in the short term.